Fig. 3
From: CAR-T cell therapy for cancer: current challenges and future directions
Challenges in CAR-T cell generation for AML: manufacturing, bone marrow niche and tumor heterogeneity role (a). Current strategies being tested in clinical trials targeting CD123, CD33, CLL-1 and CD7 antigens (b). This figure was created with Biorender.com
